Camizestrant (SERD) in HR+/HER2- Advanced Breast Cancer: SERENA-2 Trial
Medical Supporter — Мэдээллийн мэдэгдэл
Энэ нийтлэл нь олон улсын эмнэлгийн мэдээллийн эмхэтгэл бөгөөд эмнэлгийн зөвлөгөө биш; таны эмчийн оношлогоо, эмчилгээний төлөвлөгөөг орлохгүй. Энд буй мэдээлэл нь Японы томоохон эмнэлгийн байгууллагуудын нээлттэй эх сурвалжаас эмхэтгэсэн бөгөөд аливаа эмчилгээний тохиромж, үр дүн өвчтөн бүрээр өөр тул мэргэшсэн эмч тус бүрчлэн үнэлэх ёстой.
On October 26, 2022, AstraZeneca announced the positive results of the SERENA-2 Phase 2 clinical trial, evaluating Camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), in patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer.
Study Design: SERENA-2 Trial
The SERENA-2 trial is a randomized, open-label, multi-dose Phase 2 study. It compared different doses of Camizestrant (75 mg or 150 mg) against the current standard-of-care SERD, Faslodex (Fulvestrant, 500 mg), in patients who had previously received at least one line of endocrine therapy for advanced disease.
The primary endpoint was progression-free survival (PFS).
Key Results
The trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in PFS for patients receiving Camizestrant compared to those receiving Fulvestrant:
- Superior Efficacy: Both the 75 mg and 150 mg doses of Camizestrant reduced the risk of disease progression or death.
- Safety Profile: Camizestrant was well-tolerated, with a safety profile consistent with previous studies. No new safety signals were identified.
Conclusion
Dr. Mafalda Oliveira from the Vall d'Hebron Institute of Oncology stated that the SERENA-2 results provide strong evidence for the potential of Camizestrant as a new treatment option. By outperforming Fulvestrant—a standard therapy for over 20 years—Camizestrant demonstrates the importance of next-generation SERDs in addressing the needs of patients with HR+ advanced breast cancer.
Source: AstraZeneca Press Release - SERENA-2 Results
#BreastCancer #Camizestrant #SERD #HRPositive #Faslodex #CancerResearch #SERENA2
Японд эмчлүүлэхээр төлөвлөж байна уу? Мэдээлэл, тусламж хэрэгтэй юу?
Бид Японд эмчлүүлэхэд шаардлагатай мэдээллийг эмхэтгэх, Японы эмнэлгийн байгууллагуудтай холбогдох, хоёр дахь саналын зөвлөгөө зохион байгуулахад тусална.Анхны зөвлөгөө үнэгүй; зөвлөх таны дараагийн алхмыг тодорхой болгоход тусална.
Figure 1
Figure 2
Figure 3
Figure 4